Three-dimensional conformal radiation therapy for esophageal squamous cell carcinoma: is elective nodal irradiation necessary?
- PMID: 20004527
- DOI: 10.1016/j.ijrobp.2009.02.078
Three-dimensional conformal radiation therapy for esophageal squamous cell carcinoma: is elective nodal irradiation necessary?
Abstract
Purpose: To evaluate the local control, survival, and toxicity associated with three-dimensional conformal radiotherapy (3D-CRT) for squamous cell carcinoma (SCC) of the esophagus, to determine the appropriate target volumes, and to determine whether elective nodal irradiation is necessary in these patients.
Methods and materials: A prospective study of 3D-CRT was undertaken in patients with esophageal SCC without distant metastases. Patients received 68.4 Gy in 41 fractions over 44 days using late-course accelerated hyperfractionated 3D-CRT. Only the primary tumor and positive lymph nodes were irradiated. Isolated out-of-field regional nodal recurrence was defined as a recurrence in an initially uninvolved regional lymph node.
Results: All 53 patients who made up the study population tolerated the irradiation well. No acute or late Grade 4 or 5 toxicity was observed. The median survival time was 30 months (95% confidence interval, 17.7-41.8). The overall survival rate at 1, 2, and 3 years was 77%, 56%, and 41%, respectively. The local control rate at 1, 2, and 3 years was 83%, 74%, and 62%, respectively. Thirty-nine of the 53 patients (74%) showed treatment failure. Seventeen of the 39 (44%) developed an in-field recurrence, 18 (46%) distant metastasis with or without regional failure, and 3 (8%) an isolated out-of-field nodal recurrence only. One patient died of disease in an unknown location.
Conclusions: In patients treated with 3D-CRT for esophageal SCC, the omission of elective nodal irradiation was not associated with a significant amount of failure in lymph node regions not included in the planning target volume. Local failure and distant metastases remained the predominant problems.
Copyright 2010 Elsevier Inc. All rights reserved.
Similar articles
-
Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):318-28. doi: 10.1016/j.ijrobp.2004.06.260. Int J Radiat Oncol Biol Phys. 2005. PMID: 15667949 Clinical Trial.
-
[Intensity modulated radiotherapy for local-regional advanced nasopharyngeal carcinoma].Ai Zheng. 2004 Nov;23(11 Suppl):1532-7. Ai Zheng. 2004. PMID: 15566674 Chinese.
-
Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):374-87. doi: 10.1016/j.ijrobp.2004.03.010. Int J Radiat Oncol Biol Phys. 2004. PMID: 15380569 Clinical Trial.
-
Involved-field radiotherapy for esophageal squamous cell carcinoma: theory and practice.Radiat Oncol. 2016 Feb 5;11:18. doi: 10.1186/s13014-016-0589-7. Radiat Oncol. 2016. PMID: 26846932 Free PMC article. Review.
-
[Radiochemotherapy for esophageal cancer: which nodes should be irradiated?].Cancer Radiother. 2014 Oct;18(5-6):577-82. doi: 10.1016/j.canrad.2014.07.150. Epub 2014 Sep 5. Cancer Radiother. 2014. PMID: 25201634 Review. French.
Cited by
-
Three-dimensional conformal radiation for esophageal squamous cell carcinoma with involved-field irradiation may deliver considerable doses of incidental nodal irradiation.Radiat Oncol. 2012 Nov 27;7:200. doi: 10.1186/1748-717X-7-200. Radiat Oncol. 2012. PMID: 23186308 Free PMC article.
-
Comparison between the effects of elective nodal irradiation and involved-field irradiation on long-term survival in thoracic esophageal squamous cell carcinoma patients: A prospective, multicenter, randomized, controlled study in China.Cancer Med. 2020 Oct;9(20):7460-7468. doi: 10.1002/cam4.3409. Epub 2020 Aug 25. Cancer Med. 2020. PMID: 32841543 Free PMC article. Clinical Trial.
-
Trimodality therapy of esophagectomy plus neoadjuvant chemoradiotherapy improves the survival of clinical stage II/III esophageal squamous cell carcinoma patients.Oncol Rep. 2012 Aug;28(2):446-52. doi: 10.3892/or.2012.1847. Epub 2012 Jun 1. Oncol Rep. 2012. PMID: 22664791 Free PMC article.
-
Lymphopenia in Esophageal Squamous Cell Carcinoma: Relationship to Malnutrition, Various Disease Parameters, and Response to Concurrent Chemoradiotherapy.Oncologist. 2019 Aug;24(8):e677-e686. doi: 10.1634/theoncologist.2018-0723. Epub 2019 Apr 30. Oncologist. 2019. PMID: 31040254 Free PMC article.
-
Simultaneous integrated boost intensity-modulated radiotherapy in esophageal carcinoma: early results of a phase II study.Strahlenther Onkol. 2014 Oct;190(11):979-86. doi: 10.1007/s00066-014-0636-y. Epub 2014 Mar 8. Strahlenther Onkol. 2014. PMID: 24609941 Clinical Trial.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials